Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)
To assess the tolerability and the initial safety profile of Inotuzumab Ozogamicin (CMC-544) in patients with B-Cell Non-Hodgkin's Lymphoma (NHL).
Lymphoma, B-Cell
DRUG: Inotuzumab Ozogamicin (CMC-544)
Incidence and severity of adverse events, dose-limiting toxicities, and changes in laboratory test results., 4 months
Tumor response (according to the International Response Criteria for Non-Hodgkin's Lymphomas)., 4 months
To assess the tolerability and the initial safety profile of Inotuzumab Ozogamicin (CMC-544) in patients with B-Cell Non-Hodgkin's Lymphoma (NHL).